The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that Fosun Pharma’s (SHA: 600196, HKG: 2196) Alovatinib tablets will be added to the “Support Anti‑Tumor Drugs R&D for Kids (SPARK)” pilot program. The drug, a MEK1/2 selective inhibitor, is intended for the treatment of Langerhans cell histiocytosis (LCH) and low‑grade glioma in children.
What Alovatinib Brings to Pediatric Oncology
- Targeted Mechanism – Alovatinib selectively inhibits MEK1/2, a key player in the MAPK signaling pathway that drives many pediatric tumors.
- Prior Approvals – The NMPA approved the drug in May 2025 for adult LCH and histiocytic tumors and for pediatric/adolescent NF1 patients (≥2 years) with symptomatic, inoperable plexiform neurofibromas.
- SPARK Inclusion – By entering the SPARK pilot, the drug gains accelerated development support, potential expedited review, and focused resources for pediatric indications.
Strategic Implications for Fosun Pharma
- Portfolio Expansion – The move strengthens Fosun’s position in the growing pediatric oncology market, complementing its existing pipeline in solid tumors.
- Regulatory Momentum – Participation in SPARK signals a commitment to early‑stage pediatric research, potentially attracting international collaborators and investors.
- Market Differentiation – Alovatinib’s unique MEK1/2 profile distinguishes it from other MEK inhibitors, offering a differentiated therapeutic option for rare pediatric cancers.-Fineline Info & Tech
